1[1]Niwa K,Aotsuka H,Hamada H,et al. Thrombocytopenta:A risk factor for acute myocardial infarction during the acute Phase of Kawasaki disease. coron Artery Dis, 1995,6: 857-864
2[2]Choi IH, Chwae YJ, Shim WP, et al. Clonal expansion of CD+8 T cells in Kawasaki disease. J Immunol, 1997,159:481-486
3[3]Kato H, Sugimura T, Akagi T, et al. Long term consequences of kawasaki disease. Circulation, 1994,94:1279-1285
4[4]Akagi T, Kato H, Inoue O, et al. Valvular heart disease in kawasaki Syndrome. Incidence and natural history. Am Heart J, 1990,120: 366-372
5[5]Burns JC, Shike H, Gordon JB, et al. Sequelae of kawasaki disease in adolescents and young adults. J Am Coll Cardiol, 1996,28: 253-257
6[6]Sawaji Y, Haneda N,Yamaguchi S, et al. Risk factors for coronary lesions in acute kawasaki disease. In Kato H (ed): Kawasaki Disease. Elsevier Science, Amsterdam, The Netherlands, 1995,377-380
7[7]Rowley AH, Eckerley CA, Jack HM, et al. IgA plasma cells in vascular tissure of patients with kawasaki syndrome. J Immunol, 1997, 159: 5946-5955
8[8]Terai M, Shulman ST. Prevalence of coronary artery abnormalities in kawasaki disease is highly dependent on gammaglobulin dose but independent of salicylate dose. J Pediatr, 1997,131: 888-893
9[9]Sundel RP, Burns JC, Baker A, et al. Gamma globulin re treatment in kawasaki disease. J Pediatr, 1993,123:657-659
10[12]Noto N, Aynsawa M, Karasawa K, et al. Dobutamine stress echocardio graphy for detection of coronary artery stenosis in children with kawasaki disease. J Am Coll Cardiol, 1996,27:1251-1256
